Advertisement

Drugs & Aging

, Volume 21, Issue 11, pp 687–709 | Cite as

Subcutaneous Apomorphine

An Evidence-Based Review of its Use in Parkinson’s Disease
  • Dirk Deleu
  • Yolande Hanssens
  • Margaret G. Northway
Review Article

Abstract

Apomorphine, a short-acting dopamine D1 and D2 receptor agonist, was the first dopamine receptor agonist used to treat Parkinson’s disease. Subcutaneous apomorphine is currently used for the management of sudden, unexpected and refractory levodopa-induced ‘off’ states in fluctuating Parkinson’s disease either as intermittent rescue injections or continuous infusions. Other indications include the challenge test for determining the dopaminergic responsiveness and finding the appropriate dose of the drug in intermittent subcutaneous administration.

Except for a rapid on- and offset of the antiparkinsonian response with subcutaneous apomorphine, the magnitude and pattern of the motor response to single dose of subcutaneously administered apomorphine is qualitatively comparable to that of oral levodopa. Seventy-five percent of patients achieve a clinically significant improvement with a dose of apomorphine 4mg.

The efficacy of intermittent subcutaneous apomorphine injections as an add-on to levodopa therapy in advanced Parkinson’s disease was explored in one short-term, randomised, double-blind, placebo-controlled trial, one short-term and six long-term, open-label, uncontrolled studies, including a total of 195 patients. These studies provide evidence that this mode of administration was successful in aborting ‘off’ periods and improving Parkinson’s disease motor scores, but tended to increase dyskinesias. No levodopa-sparing effect was observed.

Eleven long-term, open-label, uncontrolled studies, including a total of 233 patients evaluated the efficacy of continuous subcutaneous apomorphine infusions in monotherapy or as an add-on to levodopa therapy in advanced Parkinson’s disease. These studies proved that subcutaneous apomorphine infusions are successful in aborting ‘off’ periods, reducing dyskinesias and improving Parkinson’s disease motor scores with the added benefit of a substantial levodopa-sparing effect.

The apomorphine challenge test has at least 80% overall predictive ability to clinically diagnose Parkinson’s disease across the different stages of the disease and parkinsonian syndromes. Similarly, those data also indicate that the apomorphine challenge test has a >80% ability to predict dopaminergic responsiveness across all stages of Parkinson’s disease.

Adverse events are usually mild and consist predominantly of cutaneous reactions and neuropsychiatric adverse effects. The incidence of adverse effects is higher in patients receiving continuous infusion than in those receiving intermittent pulsatile administration.

Based on the results of these studies it is recommended that subcutaneous apomorphine either as intermittent injections or continuous infusions should be offered to any suitable Parkinson’s disease patient who has difficulties in his/her management with conventional therapy. Low-dose levodopa therapy in combination with waking-day hours subcutaneous apomorphine infusion would probably be the most efficient treatment. Continuous subcutaneous apomorphine infusions should be evaluated before more invasive measures or neurosurgical interventions are contemplated.

Keywords

Levodopa Apomorphine Levodopa Therapy Dopamine Receptor Agonist Neuropsychiatric Adverse Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen der extrapyramidalen Systems. Klin Wochenschrift 1960; 38: 1236–9CrossRefGoogle Scholar
  2. 2.
    Marsden CD, Parkes JD, Quinn N. Fluctuations and disability in Parkinson’s disease: clinical aspects. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth Scientific, 1982: 96–122Google Scholar
  3. 3.
    Cantello R, Gilli M, Riccio A, et al. Mood changes associated with ‘end-of-dose’ deterioration in Parkinson’s disease: a controlled study. J Neurol Neurosurg Psychiatry 1986; 49: 1182–90PubMedCrossRefGoogle Scholar
  4. 4.
    Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson’s disease: a clinical and neuropharmacological study. Brain 1984; 107: 487–506PubMedCrossRefGoogle Scholar
  5. 5.
    Nissenbaum H, Quinn NP, Brown RG, et al. Mood swings with the ‘on-off’ phenomenon in Parkinson’s disease. N Engl J Med 1987; 310: 483–8Google Scholar
  6. 6.
    Quinn NP, Lang AE, Koller WC, et al. Painful Parkinson’s disease. Lancet 1986; I: 1366–9CrossRefGoogle Scholar
  7. 7.
    Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet 1977; I: 345–9CrossRefGoogle Scholar
  8. 8.
    Strange PG. Dopamine receptors in the basal ganglia: relevance to Parkinson’s disease. Mov Disord 1994; 8: 263–70CrossRefGoogle Scholar
  9. 9.
    Robertson GS, Robertson HA. Synergistic effects of Dl and D2 dopamine agonists on turning behaviour in rats. Brain Res 1986; 384: 387–90PubMedCrossRefGoogle Scholar
  10. 10.
    Lange KW, Rausch WD, Gsell W, et al. Neuroprotection by dopamine agonists. J Neural Transm Suppl 1994; 43: 183–201PubMedGoogle Scholar
  11. 11.
    Bedard PJ, Blanchet PJ, Levesque D, et al. Pathophysiology of L-dopa-induced dyskinesias. Mov Disord 1999; 14Suppl. 1: 4–8PubMedGoogle Scholar
  12. 12.
    Grondin R, Bedard PJ, Britton DR, et al. Potential therapeutic use of the selective dopamine Dl receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys. Neurology 1997; 49: 421–6PubMedCrossRefGoogle Scholar
  13. 13.
    Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002; 303: 791–804PubMedCrossRefGoogle Scholar
  14. 14.
    Newman-Tancredi A, Cussac D, Audinot V, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(l)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther 2002; 303: 805–14PubMedCrossRefGoogle Scholar
  15. 15.
    Newman-Tancredi A, Cussac D, Quentric Y, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(l) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 2002; 303: 815–22PubMedCrossRefGoogle Scholar
  16. 16.
    Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson’s disease management. Drugs 1993; 46: 384–93PubMedCrossRefGoogle Scholar
  17. 17.
    Wachtel H. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J Neural Transm Park Dis Dement Sect 1991; 3: 151–201PubMedCrossRefGoogle Scholar
  18. 18.
    Levant B, Dung Ling Z, Carvey PM. Dopamine D3 receptors: relevance for the drug treatment of Parkinson’s disease. CNS Drugs 1999; 12: 391–402CrossRefGoogle Scholar
  19. 19.
    Piercey MF, Hoffmann WE, Smith MW, et al. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 1996; 312: 35–44PubMedCrossRefGoogle Scholar
  20. 20.
    Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002; 41: 261–309PubMedCrossRefGoogle Scholar
  21. 21.
    Matthiessen A, Wright CRA. Researches into the chemical constitution of the opium bases. Part 1: on the action of hydrochloric acid on morphia. Proc R Soc Lond B Biol Sci 1869; 17: 455–60Google Scholar
  22. 22.
    Neumeyer JL, Lal S, Baldessarini RJ. Historical highlights of the chemistry, pharmacology, and early clinical uses of apomorphine. In: Gessa GL, Corsini GU, editors. Apomorphine and other dopaminomimetics. Vol 1. Basic pharmacology. New York: Raven Press, 1981: 1–17Google Scholar
  23. 23.
    Weill E. De l’apomorphine dans certains troubles nerveux. Lyon Med 1884; 48: 411–9Google Scholar
  24. 24.
    Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc 1951; 76: 251–3Google Scholar
  25. 25.
    Cotzias GC, Papavasiliou PS, Tolosa ES, et al. Similarities between neurologic effects of L-dopa and apomorphine. N Engl J Med 1970; 282: 31–2PubMedCrossRefGoogle Scholar
  26. 26.
    Duby SE, Cotzias GC, Papavasiliou PS, et al. Injected apomorphine and orally administered levodopa in Parkinsonism. Arch Neurol 1972; 27: 474–80PubMedCrossRefGoogle Scholar
  27. 27.
    Cotzias GC, Papavasiliou PS, Tolosa ES, et al. Treatment of Parkinson’s disease with aporphines: possible role for growth hormone. N Engl J Med 1976; 297: 567–72CrossRefGoogle Scholar
  28. 28.
    Lees AJ. Dopamine agonists in Parkinson’s disease: a look at apomorphine. Fundam Clin Pharmacol 1993; 7: 121–8PubMedCrossRefGoogle Scholar
  29. 29.
    Barker R, Duncan J, Lees AJ. Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes. Lancet 1989; I: 675–8CrossRefGoogle Scholar
  30. 30.
    Gottlieb S. FDA committee recommends approval for Viagra rival. BMJ 2000; 320: 1094PubMedCrossRefGoogle Scholar
  31. 31.
    Hagell P, Odin O. Apomorphine in the treatment of Parkinson’s disease. J Neurosci Nurs 2001; 33: 21–38PubMedCrossRefGoogle Scholar
  32. 32.
    Corsini GU, Del Zompo M, Gessa GL, et al. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. Lancet 1979; I: 954–6CrossRefGoogle Scholar
  33. 33.
    Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001; 56 (11 Suppl. 5): S1–S88PubMedCrossRefGoogle Scholar
  34. 34.
    Scarzella L, Delsedime M, Ferrero B, et al. Apomorphine SC treatment in parkinsonian patients with long term L-DOPA syndrome during L-DOPA drug holiday. J Neural Transm Suppl 1995; 45: 163–70PubMedGoogle Scholar
  35. 35.
    Nutt JG, Gancher ST, Woodward WR. Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 1988; 38: 1553–7PubMedCrossRefGoogle Scholar
  36. 36.
    Harder S, Baas H, Demisch L, et al. Dose response and concentration response relationship of apomorphine in patients with Parkinson’s disease and end-of-dose akinesia. Int J Clin Pharmacol Ther 1998; 36: 355–62PubMedGoogle Scholar
  37. 37.
    Verhagen Metman L, Locatelli ER, Bravi D, et al. Apomorphine responses in Parkinson’s disease and the pathogenesis of motor complications. Neurology 1997; 48: 369–72PubMedCrossRefGoogle Scholar
  38. 38.
    Gancher ST, Woodward WR, Gliessman P, et al. The shortduration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonism. Ann Neurol 1990, 5Google Scholar
  39. 39.
    Harder S, Baas H, Rietbrock S. Concentration-effect relationship of levodopa in patients with Parkinson’s disease. Clin Pharmacokinet 1995; 29: 243–56PubMedCrossRefGoogle Scholar
  40. 40.
    Hughes AJ, Lees AJ, Stern GM. Apomorphine in the diagnosis and treatment of parkinsonian tremor. Clin Neuropharmacol 1990; 13: 312–7PubMedCrossRefGoogle Scholar
  41. 41.
    Kempster PA, Frankel JP, Stern GM, et al. Comparison of motor response to apomorphine and levodopa in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990; 53: 1004–7PubMedCrossRefGoogle Scholar
  42. 42.
    Hughes AJ, Bishop S, Stern GM, et al. The motor response to repeated apomorphine administration in Parkinson’s disease. Clin Neuropharmacol 1991; 14: 209–13PubMedCrossRefGoogle Scholar
  43. 43.
    van Laar T, Jansen EN, Essink AW, et al. A double-blind study of the efficacy of apomorphine and its assessment in ‘off’-periods in Parkinson’s disease. Clin Neurol Neurosurg 1993; 95: 231–5PubMedCrossRefGoogle Scholar
  44. 44.
    Nicolle E, Pollak P, Serre-Debeauvais F, et al. Pharmacokinetics of apomorphine in parkinsonian patients. Fundam Clin Pharmacol 1993; 7: 245–52PubMedCrossRefGoogle Scholar
  45. 45.
    Gancher ST, Woodward WR Boucher B, et al. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989; 26: 232–8PubMedCrossRefGoogle Scholar
  46. 46.
    Colosimo C, Merello M, Hughes AJ, et al. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson’s disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996; 60: 634–7PubMedCrossRefGoogle Scholar
  47. 47.
    Merello M, Pikielny R, Cammarota A, et al. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson’s disease patients: a double-blind single-dose study. Clin Neuropharmacol 1997; 20: 165–7PubMedCrossRefGoogle Scholar
  48. 48.
    Rodriguez M, Lera G, Vaamonde J, et al. Motor response to apomorphine and levodopa in asymmetric Parkinson’s disease. J Neurol Neurosurg Psychiatry 1994; 57: 562–6PubMedCrossRefGoogle Scholar
  49. 49.
    Sam E, Jeanjean AP, Maloteaux JM, et al. Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. Eur J Drug Metab Pharmacokinet 1995; 20: 27–33PubMedCrossRefGoogle Scholar
  50. 50.
    Nutt JG, Carter JH. Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD. Neurology 2000; 54: 247–50PubMedCrossRefGoogle Scholar
  51. 51.
    Dewey Jr RB, Hutton JT, Le Witt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58: 1385–92PubMedCrossRefGoogle Scholar
  52. 52.
    Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990; 53: 96–101PubMedCrossRefGoogle Scholar
  53. 53.
    Esteban Muñoz J, Marti MJ, Marin C, et al. Long-term treatment with intermittent intranasal or subcutaneous apomorphine in patients with levodopa-related motor fluctuations. Clin Neuropharmacol 1997; 20: 245–52PubMedCrossRefGoogle Scholar
  54. 54.
    Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson’s disease: a long-term follow-up. J Neurol Neurosurg Psychiatry 1998; 65: 709–16PubMedCrossRefGoogle Scholar
  55. 55.
    Gancher ST, Nutt JG, Woodward WR. Diurnal responsiveness to apomorphine. Neurology 1987; 37: 1250–3PubMedCrossRefGoogle Scholar
  56. 56.
    Hughes AJ, Lees AJ, Stern GM. The motor response to sequential apomorphine in parkinsonian fluctuations. J Neurol Neurosurg Psychiatry 1991; 54: 358–60PubMedCrossRefGoogle Scholar
  57. 57.
    Grandas F, Obeso JA. Motor response following repeated apomorphine administration is reduced in Parkinson’s disease. Clin Neuropharmacol 1989; 12: 14–22PubMedCrossRefGoogle Scholar
  58. 58.
    Gancher ST, Nutt JG, Woodward WR. Time course of tolerance to apomorphine in parkinsonism. Clin Pharmacol Ther 1992; 52: 504–10PubMedCrossRefGoogle Scholar
  59. 59.
    Gancher ST, Woodward WR, Nutt JG. Apomorphine tolerance in Parkinson’s disease: lack of a dose effect. Clin Neuropharmacol 1996; 19: 59–64PubMedCrossRefGoogle Scholar
  60. 60.
    Obeso JA, Luquin MR, Grandas F, et al. Motor response to repeated dopaminergic stimulation in Parkinson’s disease. Clin Neuropharmacol 1992; 15: 75–9PubMedCrossRefGoogle Scholar
  61. 61.
    Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165–70PubMedCrossRefGoogle Scholar
  62. 62.
    Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson’s disease: clinical utility and lack of tolerance. Mov Disord 1995; 10: 37–43PubMedCrossRefGoogle Scholar
  63. 63.
    Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1998; 64: 573–6PubMedCrossRefGoogle Scholar
  64. 64.
    Lozano AM, Lang AE, Levy R, et al. Neuronal recordings in Parkinson’s disease patients with dyskinesias induced by apomorphine. Ann Neurol 2000; 47 (4 Suppl. 1): S141–6PubMedGoogle Scholar
  65. 65.
    Levy R, Dostrovsky JO, Lang AE, et al. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson’s disease. J Neurophysiol 2001; 86: 249–60PubMedGoogle Scholar
  66. 66.
    Merello M, Lees AJ, Balej J, et al. GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine. Mov Disord 1999; 14: 481–3PubMedCrossRefGoogle Scholar
  67. 67.
    Muguet D, Broussolle E, Chazot G. Apomorphine in patients with Parkinson’s disease. Biomed Pharmacother 1995; 49: 197–209PubMedCrossRefGoogle Scholar
  68. 68.
    van der Geest R, Kruger P, Gubbens-Stibbe JM, et al. Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson’s disease. J Chromatogr B Biomed Sci Appl 1997; 702: 131–41PubMedCrossRefGoogle Scholar
  69. 69.
    van der Geest R, van Laar T, Kruger PP, et al. Pharmaco-kinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson’s disease. Clin Neuropharmacol 1998; 21: 159–68PubMedGoogle Scholar
  70. 70.
    Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6: 429–53PubMedCrossRefGoogle Scholar
  71. 71.
    Przedborski S, Levivier M, Raftopoulos C, et al. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov Disord 1995; 10: 28–36PubMedCrossRefGoogle Scholar
  72. 72.
    Hofstee DJ, Neef C, van Laar T, et al. Pharmacokinetics of apomorphine in Parkinson’s disease: plasma and cerebrospinal fluid levels in relation to motor responses. Clin Neuropharmacol 1994; 17: 45–52PubMedCrossRefGoogle Scholar
  73. 73.
    Poewe W, Kleedorfer B, Gerstenbrand F, et al. Die Behandelung von Parkinsonpatienten mit L-dopa-wirkungsfluktuation mittels subkutanen Apomorphingaben. Acta Neurol 1989; 16: 73–7Google Scholar
  74. 74.
    Østergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo-controlled study. J Neurol Neurosurg Psychiatry 1995; 58: 681–7PubMedCrossRefGoogle Scholar
  75. 75.
    Merello M, Leigurda R. Treatment of motor fluctuations in Parkinson’s disease with subcutaneous injections of apomorphine [in Spanish]. Medicina (B Aires) 1995; 55: 5–10Google Scholar
  76. 76.
    Stibe C, Lees A, Kempster PA, et al. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988; I(8582): 403–6CrossRefGoogle Scholar
  77. 77.
    Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion: a comparative chronic study. Adv Neurol 1993; 60: 653–5PubMedGoogle Scholar
  78. 78.
    Poewe W, Kleedorfer B, Wagner M, et al. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson’s disease. Adv Neurol 1993; 60: 656–9PubMedGoogle Scholar
  79. 79.
    Wenning GK, Bösch S, Luginger E, et al. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson’s disease. Adv Neurol 1999; 80: 545–8PubMedGoogle Scholar
  80. 80.
    Stocchi F, Vacca L, De Pandis MF, et al. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson’s disease: long-term results. Neurol Sci 2001; 22: 93–4PubMedCrossRefGoogle Scholar
  81. 81.
    Kaňovsky P, Kubová D, Bareš M, et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 2002; 17: 188–91PubMedCrossRefGoogle Scholar
  82. 82.
    Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord 2002; 17: 1235–41PubMedCrossRefGoogle Scholar
  83. 83.
    Christmas TJ, Kempster PA, Chappie CR, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988; II: 1451–3CrossRefGoogle Scholar
  84. 84.
    Mathers SE, Kempster PA, Swash M, et al. Constipation and paradoxical puborectalis contraction in anismus and Parkinson’s disease: a dystonic phenomenon? J Neurol Neurosurg Psychiatry 1988; 51: 1503–7PubMedCrossRefGoogle Scholar
  85. 85.
    Mathers SE, Kempster PA, Law P, et al. Anal sphincter dysfunction in Parkinson’s disease. Arch Neurol 1989; 46: 1061–4PubMedCrossRefGoogle Scholar
  86. 86.
    Hunter PC, Crameri J, Austin S, et al. Response of parkinsonian swallowing dysfunction to dopaminergic stimulation. J Neurol Neurosurg Psychiatry 1997; 63: 579–83PubMedCrossRefGoogle Scholar
  87. 87.
    Tison F, Wiart L, Guatterie M, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease. Mov Disord 1996; 11: 729–32PubMedCrossRefGoogle Scholar
  88. 88.
    Factor SA, Brown DL, Molho ES. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson’s disease. Mov Disord 2000; 15: 167–9PubMedCrossRefGoogle Scholar
  89. 89.
    Kempster PA, Lees AJ, Crichton P, et al. Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson’s disease and its treatment with apomorphine. Mov Disord 1989; 4: 47–52PubMedCrossRefGoogle Scholar
  90. 90.
    Bareš M, Brazdil M, Kanovsky P, et al. The effect of apomorphine administration on smooth pursuit ocular movements in early Parkinsonian patients. Parkinsonism Relat Disord 2003; 9: 139–44PubMedCrossRefGoogle Scholar
  91. 91.
    Deleu D. Neurology in clinical practice: an algorithmic approach [online]. Available from URL: http//www.neuroweb.us/ [Accessed 2004 Feb 25]
  92. 92.
    Hughes AJ, Colosimo C, Kleedorfer B, et al. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992; 55: 1009–13PubMedCrossRefGoogle Scholar
  93. 93.
    Wenning C, Ben-Shlomo Y, Magalhaes M, et al. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995; 58: 160–6PubMedCrossRefGoogle Scholar
  94. 94.
    Litvan I, Mangone CA, McKee, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996; 61: 615–20CrossRefGoogle Scholar
  95. 95.
    Hughes AJ. Apomorphine test in the assessment of parkinsonian patients: a meta-analysis. Adv Neurol 1999; 80: 363–8PubMedGoogle Scholar
  96. 96.
    MacMahon. Use of apomorphine in clinical practice. Adv Neurol 1999; 80: 529–33PubMedGoogle Scholar
  97. 97.
    Rossi P, Colosimo C, Moro E, et al. Acute challenge with apomorphine and levodopa in Parkinsonism. Eur Neurol 2000; 43: 95–101PubMedCrossRefGoogle Scholar
  98. 98.
    Oertel WH, Gasser T, Ippisch R, et al. Apomorphine test for dopaminergic responsiveness. Lancet 1989; I: 1262–3CrossRefGoogle Scholar
  99. 99.
    Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990; 336: 1262–3Google Scholar
  100. 100.
    Hughes AJ, Lees AJ, Stern GM. Challenge test to predict the dopaminergic response in untreated Parkinson’s disease. Neurology 1991; 41: 1723–5PubMedCrossRefGoogle Scholar
  101. 101.
    D’Costa DF, Abbott RJ, Pye IF, et al. The apomorphine test in parkinsonian syndromes. J Neurol Neurosurg Psychiatry 1991; 54: 870–2PubMedCrossRefGoogle Scholar
  102. 102.
    Gasser T, Schwarz J, Arnold G, et al. Apomorphine test for dopaminergic responsiveness inpatients with previously untreated Parkinson’s disease. Arch Neurol 1992; 49: 1131–4PubMedCrossRefGoogle Scholar
  103. 103.
    Bonuccelli U, Piccini P, Del Dotto P, et al. Apomorphine test in de novo Parkinson’s disease. Funct Neurol 1992; 7: 295–8PubMedGoogle Scholar
  104. 104.
    Bonuccelli U, Piccini P, Del Dotto P, et al. Apomorphine test for dopaminergic responsiveness: a dose assessment study. Mov Disord 1993; 8: 158–64PubMedCrossRefGoogle Scholar
  105. 105.
    Schelosky L, Hierholzer J, Wissel J, et al. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by I123IBZM-SPECT. Mov Disord 1993; 8: 453–8PubMedCrossRefGoogle Scholar
  106. 106.
    Baas H, Harder S, Biircklin F, et al. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. Clin Neuropharmacol 1998; 21: 86–92PubMedGoogle Scholar
  107. 107.
    Contin M, Riva R, Martinelli P, et al. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson’s disease. Neurology 1994; 44: 1287–92PubMedCrossRefGoogle Scholar
  108. 108.
    Acland KM, Churchyard A, Fletcher CL, et al. Panniculitis in association with apomorphine infusion. Br J Dermatol 1998; 138: 480–2PubMedCrossRefGoogle Scholar
  109. 109.
    van Laar T, van Hilten B, Neef C, et al. The role of EDTA in provoking allergic reactions to subcutaneous infusions of apomorphine in patients with Parkinson’s disease: a histologic study. Mov Disord 1998; 13: 52–5PubMedCrossRefGoogle Scholar
  110. 110.
    Ellis C, Lemmens G, Parkes JD, et al. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat Disord 1997; 3: 103–7PubMedCrossRefGoogle Scholar
  111. 111.
    Goulet M, Morissette M, Calon F, et al. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-l,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis. Neuroscience 1997; 79: 497–507PubMedCrossRefGoogle Scholar
  112. 112.
    Stocchi F, De Pandis MF, Delfino FA, et al. Transient atrial fibrillation after subcutaneous apomorphine bolus. Mov Disord 1996; 11: 584–5PubMedCrossRefGoogle Scholar
  113. 113.
    Sabatini U, Rascol O, Rascol A, et al. Migraine attacks induced by subcutaneous apomorphine in two migrainous parkinsonian patients. Clin Neuropharmacol 1990; 13: 264–7PubMedCrossRefGoogle Scholar
  114. 114.
    Vermersch P, Mounier-Vehier F, Caron J, et al. Severe oedema after subcutaneous apomorphine in Parkinson’s disease [letter]. Lancet 1989; II: 802CrossRefGoogle Scholar
  115. 115.
    Loewe R, Puspok-Schwarz M, Petzelbauer P. Apomorphine hyperpigmentation [in German]. Hautarzt 2003; 54: 58–63PubMedGoogle Scholar
  116. 116.
    Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 2002; 324: 1483–7PubMedCrossRefGoogle Scholar
  117. 117.
    Homann CN, Wenzel K, Suppan K, et al. Sleep attacks with apomorphine. Wien Klin Wochenschr 2002; 114: 430–1PubMedGoogle Scholar
  118. 118.
    Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson’s disease? Drugs Aging 2001; 18: 389–96PubMedCrossRefGoogle Scholar
  119. 119.
    Battaglia G, Busceti CL, Cuomo L, et al. Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopamine terminals following MPTP injection in mice. Neuropharmacology 2002; 42: 367–73PubMedCrossRefGoogle Scholar
  120. 120.
    Gassen M, Glinka Y, Pinchasi B, etal. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharm 1996; 308: 219–25CrossRefGoogle Scholar
  121. 121.
    Grunblatt E, Mandel S, Gassen M, et al. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. J Neural Transm Suppl 1999; 55: 57–70PubMedGoogle Scholar
  122. 122.
    Grunblatt E, Mandel S, Berkuzki T, et al. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord 1999; 14: 612–8PubMedCrossRefGoogle Scholar
  123. 123.
    Piccini P, Weeks RA, Brooks DJ, et al. Alterations in opioid receptor binding in Parkinson’s disease patients with levodopa-induced dyskinesias. Ann Neurol 1997; 42: 720–6PubMedCrossRefGoogle Scholar
  124. 124.
    Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problems of dyskinesia in Parkinson’s disease. Mov Disord 1998; 13: 871–6PubMedCrossRefGoogle Scholar
  125. 125.
    Blanchet PJ, Calon F, Morissette M, et al. Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model. Adv Neurol 2001; 86: 337–44PubMedGoogle Scholar
  126. 126.
    Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs 1998; 55Suppl. 1: 1–9PubMedCrossRefGoogle Scholar
  127. 127.
    Youdim MB, Gassen M, Gross A, et al. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. J Neural Transm Suppl 2000; 58: 83–96PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Dirk Deleu
    • 1
  • Yolande Hanssens
    • 2
  • Margaret G. Northway
    • 3
  1. 1.Department of Neurology (Medicine)Hamad Medical CorporationDohaState of Qatar
  2. 2.Department of PharmacyHamad Medical CorporationDohaState of Qatar
  3. 3.Department of Pharmacology and TherapeuticsSultan Qaboos UniversityAl KhodSultanate of Oman

Personalised recommendations